173 related articles for article (PubMed ID: 32476541)
1. Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.
Weil CR; Qian Y; Von Eyben R; Daadi SE; Corbelli KS; Rosenberg SA; Advani RH; Hoppe RT
Leuk Lymphoma; 2020 Oct; 61(10):2428-2434. PubMed ID: 32476541
[TBL] [Abstract][Full Text] [Related]
2. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
3. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
Chisesi T; Federico M; Levis A; Deliliers GL; Gobbi PG; Santini G; Luminari S; Linfomi MB;
Ann Oncol; 2002; 13 Suppl 1():102-6. PubMed ID: 12078888
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153
[TBL] [Abstract][Full Text] [Related]
5. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
6. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
8. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
9. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
10. ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do?
Connors JM
Clin Lymphoma; 2005 Jun; 6(1):50-1. PubMed ID: 15989708
[No Abstract] [Full Text] [Related]
11. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
[TBL] [Abstract][Full Text] [Related]
12. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
Borchmann P
Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
[TBL] [Abstract][Full Text] [Related]
13. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
[TBL] [Abstract][Full Text] [Related]
14. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
15. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
16. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
Kelly KM; Hutchinson RJ; Sposto R; Weiner MA; Lones MA; Perkins SL; Massey V;
Ann Oncol; 2002; 13 Suppl 1():107-11. PubMed ID: 12078889
[TBL] [Abstract][Full Text] [Related]
18. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
20. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
